A Randomized Placebo-Controlled Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia.

Trial Profile

A Randomized Placebo-Controlled Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2013

At a glance

  • Drugs Asenapine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms RHEA
  • Most Recent Events

    • 06 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 27 May 2010 Actual patient number changed from 702 to 831 as reported by ClinicalTrials.gov.
    • 14 Sep 2009 Results presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top